Online inquiry

IVTScrip™ mRNA-Human ACSL6, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK14249MR)

This product GTTS-WK14249MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ACSL6 protein. This product can be used in Astrocyte-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001009185.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 23305
UniProt ID Q9UKU0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ACSL6, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK14249MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK17703MR IVTScrip™ mRNA-Human AGMAT, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGMAT
GTTS-WK20822MR IVTScrip™ mRNA-Human Alkaline phosphatase, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Alkaline phosphatase
GTTS-WK23321MR IVTScrip™ mRNA-Human ASNSD1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASNSD1
GTTS-WK1936MR IVTScrip™ mRNA-Human CDC42_1, (Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDC42_1
GTTS-WK9366MR IVTScrip™ mRNA-Human ABHD17A, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABHD17A
GTTS-WK18714MR IVTScrip™ mRNA-Human ALG14, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALG14
GTTS-WK26177MR IVTScrip™ mRNA-Human ARG2, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARG2
GTTS-WK19501MR IVTScrip™ mRNA-Human AGK, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGK
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW